37 results about "Synovial sarcoma" patented technology

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI / SNF) complexes in SS cells by increasing levels of wild type SS18 and / or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC50 value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

The present invention relates to Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) inhibitors for use in methods of treating BAF-complex deficient cancer. The present invention further provides methods for identifying ATR inhibitors for use in the treatment of BAF complex gene mutant or deficient cancers. Medical uses and methods relating to the treatment of synovial sarcoma using ATR inhibitors are also provided.

The invention provides a method for constructing an immune-sound synovial sarcoma xenograft mouse model, which includes the cultivation of the P0 generation: first resuscitating the tumor tissue block of a synovial sarcoma patient stored in a liquid nitrogen environment, and then under aseptic conditions It was transplanted into immunodeficient mice; normal immune mice were pretreated with cyclosporine; culture of Px generation: the tumor tissue pieces grown in any generation of mice from P0 to Px‑1 generation were inoculated into the above-mentioned From the mice pretreated with cyclosporine, the Px generation mice were formed; the cultivation of the Py generation: take the synovial sarcoma tumor tissue pieces grown in any generation of mice from the Px generation to the Py-1 generation above and inoculate them into normal immune cells. In the mouse body, until the tumor tissue grows in the body, the culture of the Py generation is completed. The invention improves the problem that the traditional PDX model has no immune system, provides an in vivo model for the research of tumor immunotherapy, and broadens the application range of the PDX model.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

The invention relates to a preparation method of a synovial sarcoma cell line hSS-005R. The synovial sarcoma cell line is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:C201911; the preparation method comprises primary culture and subculture. The new human synovial sarcoma cell line is established, has stable properties and can achieve stable passage several times. The established human synovial sarcoma cell line has the advantages of a high tumor formation rate, a short incubation period, good homogeneity and the like on the premise of retaining main clinical biological characteristics, so that a synovial sarcoma cell bank is enriched, a synovial sarcoma animal model can be successfully prepared, the animal model can be used for basic research and drug screening, powerful scientific research data is provided for research based on the genetic background of Chinese population, and a new test material is also provided for testing the sensitivity and drug resistance of clinical anticancer drugs during in-vivo research experiments before clinical use of new drugs.